Substance P (SP) is a neuropeptide that can modulate inflammatory mediator release through activation of NK 1 receptors (NK 1 R). Some studies have also suggested the involvement of SP in lipopolysaccharide (LPS)-induced fever. However, the precise contribution of this neuropeptide to the pathways activated during fever is unknown. In this study we investigated the effect of a selective NK 1 R antagonist, SR140333B, on the febrile response induced by LPS and cytokines. Our results show that the systemic injection of SR140333B did not modify the fever induced by LPS at a dose that is able to reduce protein extravasation induced by SP in the skin. On the other hand, intracerebroventricular administration of SR140333B significantly reduced the fever induced by peripheral injection of LPS. These data emphasize an important role for SP in the central nervous system during the febrile response to LPS, and are reinforced by the fact that intracerebroventricular injection of SP also induced fever in a dose-dependent manner in captopril-treated rats. Considering that the febrile response can result from the generation of several endogenous pyrogens, among them interleukin (IL)-1β and macrophage inflammatory protein-1α (CCL3/MIP-1α), we also examined the effect of SR140333B on the fever induced by these cytokines which act through prostaglandin-dependent andindependent mechanisms, respectively. Surprisingly, SR140333B did not modify the febrile response to IL-1β or CCL3/MIP-1α. Altogether these data suggest that the central action of SP is essential for LPS-, but not for IL-1β-or CCL3/MIP-1α-induced fever.
Introduction
The febrile response is a key phenomenon of the acute phase reaction, which is also characterized by changes in several physiological parameters such as the levels of liver proteins, hormones and cells in blood, sleep phases, food intake, and others (Zeisberger, 1999) . Due to the increased body temperature, defense mechanisms are stimulated, making the febrile response relevant to protection of the body's integrity against invading organisms (Blatteis and Sehic, 1998) . The main brain area involved in the control of the body temperature is the anterior hypothalamic pre-optic area (POA), which transduces the information received to a neuronal signal that changes the temperature set point, resulting in fever (Blatteis and Sehic, 1998; Zeisberger, 1999) . The systemic administration of LPS to experimental animals represents one of the classical models of fever induction since it reproduces what naturally occurs during inflammatory and infectious processes. LPS stimulates macrophages, monocytes, and other cells to release cytokines, which can act as endogenous pyrogens to promote fever (Roth and De Souza, 2001) . Interleukin (IL)-1β was the first-described endogenous pyrogen (Dinarello, 1984) and despite the subsequent identification of others it probably remains the most studied (Helle et al., 1988; Watanabe, 1992; Zampronio et al., 1994) . A number of mechanisms have been suggested to explain how the peripherally produced endogenous pyrogens exert their effects on the central nervous system (CNS) to produce fever (Banks et al., 1991; Banks et al., 1994; Cao et al., 1996; Konsman et al., 2004) , but it is clear that the synthesis and release of central mediators is required to bring about the necessary changes in the hypothalamic set point. Several central mediators have been proposed including prostaglandins E 2 (PGE 2 ) and F 2α (PGF 2α ) (Coelho et al., 1993; Milton, 1989) , corticotrophin releasing factor (CRF) (Rothwell, 1989; Zampronio et al., 2000) , endothelin-1 (ET-1) (Fabricio et al., 1998) , endogenous opioids (Benamar et al., 2000; Fraga et al., 2008) , endocannabinoids (Fraga et al., 2009 ) and also substance P (SP) (Blatteis et al., 1994) . Among these, prostaglandins derived from both peripheral and central sources appear to be important (Ivanov et al., 2003; Steiner et al., 2006) . The febrile response is triggered by the action of PGE 2 on POA neurons mainly through the EP 3 receptor (EP 3 R) (Lazarus et al., 2007; Oka et al., 2003) which would relief the tonic inhibition that these neurons exert over the dorsomedial hypothalamus to activate brown adipose tissue thermogenesis and over the rostral raphe pallidus to elicit cutaneous vasoconstriction (Nakamura et al., 2005; Rathner et al., 2008; Yoshida et al., 2009 ) probably through two separate pathways (Nakamura et al., 2009; Ootsuka and McAllen, 2006) . Nonetheless, how the other central mediators interact with these neurons in the hypothalamus to produce fever is less known. There is also the possibility that different central mediators are involved in different pathways for fever induction. For example, endogenous opioids are involved in the febrile response induced by LPS and several cytokines but not by IL-1β (Fraga et al., 2008) , while ET-1 is involved in the febrile response induced only by LPS and pre-formed pyrogenic factor , but not in the fever induced by other cytokines. Meanwhile, both endogenous opioids and ET-1 induce fever by prostaglandin-independent mechanisms (Fabricio et al., 2005; Fraga et al., 2008) .
Although substance P may be involved in mediating certain febrile responses, its actions are not well understood. Substance P (SP: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gli-Leu-Met-NH 2 ) is found in primary afferent fibers [A-δ, C and capsaicinsensitive fibers (Cahill and Coderre, 2002) ] as well as in the CNS (Hurd et al., 1999) , and there are several studies showing its participation in inflammatory processes and, to a lesser extent, in the febrile response. In the CNS, SP is present in several structures, including the POA [for review see (Otsuka and Yoshioka, 1993) ]. Although the main source of SP is neuronal cells, some studies with rodents have shown that SP can also be synthesized by macrophages, eosinophils, lymphocytes, dendritic cells, and others (Bost, 2004; Ho et al., 1997; Satake and Kawada, 2006) . SP effects are mediated almost exclusively by the metabotropic NK 1 R, which is expressed in several structures of the CNS, including the putamen, caudate nucleus and hypothalamus, and in the peripheral nervous system, where it is found in dorsal root ganglia and intestinal intrinsic neurons [for review see (Harrison and Geppetti, 2001; Tuluc et al., 2009)] . Furthermore, the NK 1 R can also be expressed by immune cells such as macrophages, neutrophils, lymphocytes and mast cells (Cooke et al., 1998; Ho et al., 1997; Lai et al., 1998; Lambrecht et al., 1999) .
The administration of NK 1 R antagonists reduced neutrophil migration induced by P. nigriventer venom (Costa et al., 2002) or formalin (Santos et al., 2004) , when systemically injected, and reduced the febrile response to LPS when administered centrally (Balasko et al., 2000; Szelenyi et al., 1997) in laboratory animals, highlighting the participation of SP in these events. In addition, some in vitro experiments have shown that SP induces pro-inflammatory cytokine release from rodent macrophages and granulocytes (Delgado et al., 2003; Yaraee et al., 2003) , which is crucial to the development of the inflammatory and febrile responses and enhances the release of pro-inflammatory cytokines in response to LPS (Berman et al., 1996) . Moreover, LPS itself can increase the NK 1 R expression in some of these cells (Bost, 2004) .
In view of such considerations, the present study aimed to investigate, using a selective non-peptide NK 1 R antagonist SR140333B, whether substance P, released in the periphery or the CNS, participates in the febrile response induced by LPS and two endogenous pyrogens: IL-1β, which induces a prostaglandin-dependent fever, and CCL3/MIP-1α, which induces a prostaglandin-independent fever in conscious rats. In addition, we assessed the effects of centrally administered substance P on body temperature in this species.
Results

Peripheral injection of SR140333
Control animals treated only with vehicle or SR140333B showed a small increase in body temperature over baseline values, returning to pre-injection temperature after 1 h and remaining at this level up to 6 h after administration. In sharp contrast, those given LPS (30 μg/kg, i.p.) displayed an increase in body temperature that peaked after around 2.5 h and continued elevated for the remainder of the observation period. Prior injection of the NK 1 R antagonist SR140333B (0.3 mg/kg, data not shown or 1 mg/kg, i.p.) failed to impede the development of LPS-induced fever ( Fig. 1A and B). A higher dose of SR140333B (3 mg/kg, i.p.) was tested but, in combination with LPS, this dose induced a significant decrease in body temperature between 0 and 1.5 h (around 0.7°C) after injection, which made the interpretation of the results difficult (data not shown). SR140333B (1 mg/kg, i.p.) alone did not alter body temperature from baseline ( Fig. 1C) . To verify if this dose of SR140333B blocked the peripheral actions of SP we examined the effect of this treatment on protein extravasation. Intradermal injection of SP induced a significant increase in Evans blue extravasation when compared to saline in vehicle-treated animals ( Fig. 1D ). As expected, the treatment of the animals with SR140333B, at the same dose that did not affect the febrile response, significantly reduced the protein extravasation by 81% (Fig. 1D ).
Central injection of SR140333B
In the next set of experiments we injected SR140333B or the vehicle into the lateral ventricle of the animals. Control animals treated only with the vehicle or SR140333B showed much smaller changes in body temperature than in the previous set of experiments. The pre-treatment of the animals with SR140333B effectively reduced the febrile response induced by LPS (Fig. 2 ). Fig. 2A shows the time-course of the reduction in the febrile response induced by the higher dose of SR140333B (3 μg, i.c.v.). This dose of SR140333B reduced the fever index by 85% (Fig. 2B) . A lower dose of SR140333B
(1 μg, i.c.v.) also significantly reduced the febrile response (a reduction of 50% in the fever index) to LPS while SR140333B at 0.3 μg (i.c.v.) did not significantly change this response (Fig. 2B ). No changes in body temperature were seen in animals which received the higher dose of SR140333B or vehicle alone (Fig. 2C ).
Febrile response induced by SP
In our attempts to induce a febrile response through the i.c.v. injection of SP we tested different doses ranging from 15 to 1000 ng of SP. The responses, however, were not consistent since only a few animals showed an increase in body temperature when injected with SP (from 200 ng up to 1000 ng, data not shown). We then treated the animals with captopril 5 μg, i.c.v. 30 min before any injection. The injection of 250 ng of SP did not modify the body temperature of animals; however, the injection of SP (500 or 750 ng, i.c.v., 2 μl) in captopril-treated animals induced a febrile response which started around 2 h after injection and persisted until the end of the experiment (Fig. 3A) . The treatment of the animals with SR140333B, at the same dose that reduced the febrile response to LPS (3 μg, i.c.v.), also completely blocked the febrile response to SP (500 ng, i.c.v., Fig. 3B ). Since no difference was found between the 500 ng SP-treated group and the vehicle plus 500 ng SP-treated group, these data were combined in Fig. 3C .
Febrile response induced by IL-1β and CCL3/MIP-1α
Intracerebroventricular injection of IL-1β (3.12 ng, i.c.v.) clearly induced a significant febrile response that started around 1 h after injection and persisted until 6 h. Surprisingly, the treatment of the animals with SR140333B (3 μg) did not change this response ( Fig. 4A and B) . CCL3/MIP-1α (500 pg) also induced a febrile response that started around 3 h and lasted up to 6 h. Similarly, SR140333B was not able to reduce the febrile response induced by this cytokine ( Fig. 4C and D) .
Discussion
The data reported here show that the febrile response induced by LPS in rats is dependent on the activation of central, but not peripheral, NK 1 R. On the other hand, NK 1 R antagonist treatment (i.p. or i.c.v.) did not affect basal body temperature, suggesting that this peptide is not involved in thermoregulatory mechanisms under normal conditions. Meanwhile, our other findings show that substance P is not involved in the febrile response induced by IL-1β or CCL3/MIP-1α. The NK 1 R antagonist used here was particularly interesting for the investigation of the peripheral action of SP since there is evidence that this antagonist does not cross the blood-brain barrier (Jung et al., 1994) . We found that the intraperitoneal administration of SR140333B at a dose of 1.0 mg/kg was not able to reduce LPS-induced fever. To be sure that this dose was sufficient to reduce SP peripheral effects, we tested the effect of this treatment on plasma extravasation induced by SP. This event is caused by SP directly activating NK 1 R on endothelial cells (Bowden et al., 1994) or through the release of other mediators (Harrison and Geppetti, 2001; Maggi, 1997) . Indeed, peripherally administered SR140333B reduced the plasma extravasation caused by SP by about 81%, indicating that this antagonist is effective when administered peripherally and confirming that the peripheral release of SP to act on NK 1 R is not relevant to the febrile response induced by LPS.
However, it has been shown by others that SP does participate in LPS-induced fever (Blatteis et al., 1994; Szelenyi et al., 1997) . These studies already indicated that centrally released SP could be important for the febrile response using other antagonists. Indeed, there is evidence for the particularly high expression of SP receptors in the rat hypothalamus, a region critically involved in temperature control and fever responses (Tsuchida et al., 1990) . Also, there is evidence for the presence of SP and its precursor preprotachykinin A in the hypothalamus of primates and rats (Gautreau and Kerdelhue, 1998; Hurd et al., 1999) . Therefore, all the functional requirements for the local formation, release and action of SP appear to be present in the hypothalamus. In addition, the efficacy of centrally injected SR140333B in reducing LPS-induced fever would suggest that this pyrogen raises central SP levels.
Thus, LPS may promptly mobilize SP and the participation of the latter in fever induction by this agent appears to be essential to the process since the blockade of the response by the centrally administered NK 1 R antagonist SR140333B is evident from the onset of the fever. LPS is a potent stimulus for SP production and secretion both peripherally (Ng et al., 2008; Wang et al., 2008) and also in the spinal cord (Bret-Dibat et al., 1994) . Thus, since SP increases body temperature in rats and guinea pigs (Blatteis et al., 1994; Szelenyi et al., 1997) , the ability of LPS to trigger SP-mediated fever is not entirely unexpected. On the other hand, the induction of fever only in captopril-treated rats is somehow different from what was reported previously. In fact, we actually observed that the temperature variation among the animals injected with SP alone was quite high in our experience with fever induction. This raised the possibility that variations in SP metabolism among the animals could trigger the observed temperature variation. Angiotensin-converting enzyme (ACE) has been reported to be among the enzymes that metabolize SP (Skidgel and Erdos, 2004) . Since the majority of ACE inhibitors, including captopril, do not cross the blood-brain barrier we decided to inject it directly into the brain. The treatment of the animals with this drug allowed us to observe a more consistent effect of SP in causing fever. However, it is also known that bradykinin can induce fever (Coelho et al., 1997) and, therefore, the febrile response observed after captopril injection could be a result of an increase in bradykinin levels due to ACE inhibition. However, this does not appear to be the case, since the administration of the NK 1 R antagonist was able to block the febrile response, suggesting that SP is, with its metabolism blocked, the only substance responsible for the observed fever.
It has been shown that systemic injection of LPS quite rapidly enhances the expression of mRNA for IL-1β, IL-6 and TNF-α in the mouse hypothalamus (Goujon et al., 1996; Pitossi et al., 1997) . Considering that IL-1β can facilitate the release of SP from neurons (Morioka et al., 2002) , we investigated whether IL-1β-induced fever was mediated via SP production. However, SR140333B, at a dose that reduces 85% of the LPSinduced fever, did not alter the fever induced by IL-1β injected i.c.v, suggesting that this cytokine does not cause fever via SP release in the brain. Another possibility that should be considered is that SP, once released after LPS injection, induces the release of IL-1β which in turn causes fever. Although to our knowledge there is no evidence that LPS can directly bring about the release of SP in the CNS, there is evidence supporting the possibility that SP acts on astrocytes to release IL-1β (Martin et al., 1992) . That would explain the effectiveness of SR140333B against LPS-induced fever and not in that induced by IL-1β; however, this hypothesis needs further investigation.
IL-1β induces fever by a prostaglandin-dependent pathway since it has been shown that the non-steroidal anti-inflammatory drug indomethacin inhibits the febrile response to this cytokine (Hashimoto, 1991) . In addition, it has been shown that mice deficient in microsomal prostaglandin E synthase-1, the final PGE 2 synthesizing enzyme, do not develop fever after IL-1β peripheral injection (Saha et al., 2005) , although the expression of this and other pyrogenic cytokines is increased in the brain of these animals (Nilsberth et al., 2009b) . However, the febrile response is the result of a complex interplay between various cytokines and particularly the fever induced by LPS in rats is believed to involve prostaglandin-dependent and -independent mechanisms Nilsberth et al., 2009a; Strijbos et al., 1992) .
Since SP does not appear to mediate the IL-1β (and, therefore, prostaglandin-dependent) febrile response we decided to test the possible involvement of SP in the febrile response induced by CCL3/MIP-1α. Although it has been recently shown that CCL3/MIP-1α is not involved in LPSinduced fever (Soares et al., 2009) , this cytokine does induce fever by a prostaglandin-independent pathway (Melo Soares et al., 2006) . Nevertheless, in the present study the NK 1 R antagonist was not effective even in the prostaglandinindependent fever generated by CCL-3/MIP-1α. We mentioned before that different central mediators are involved in different pathways for fever induction. We have shown that endogenous opioids are not involved in the febrile response induced by IL-1β (Fraga et al., 2008) . However, endogenous opioids induce fever independently of prostaglandin synthesis and are important in the febrile response induced by a CCL3/MIP-1α and ET-1 (mediators that also induce fever by prostaglandin-independent pathways) (Fraga et al., 2008) . In a different way, we showed in this study that substance P is not involved in both IL-1β-and CCL3/MIP-α-induced fever. Therefore, the exact position of substance P in the fever cascade remains to be elucidated, although it does not appear to be downstream from IL-1β or CCL3/MIP-1α. In our opinion, the definition of this neuropeptide's position in the network of cytokines and mediators induced during the febrile response comes before any speculation on how it could be activating heat conservation/production mechanisms.
In summary, we showed here that a central, rather than a peripheral action of SP through NK 1 R is relevant to LPSinduced fever. However, this neuropeptide is not involved in the febrile response triggered by IL-1β, which elicits a prostaglandin-dependent fever, or CCL3/MIP-1α, which causes a prostaglandin-independent fever. SP may participate in the febrile response induced by other endogenous pyrogens or it could be released before IL-1β or CCL3/MIP-1α; therefore, the precise role of substance P in the febrile response to LPS injection still needs further investigation. 
4.
Experimental procedures
Animals
Experiments were conducted using male Wistar rats weighing 180 ± 20 g, housed at 22 ± 2°C under a 12:12 h light-dark cycle (lights on at 07:00) and with free access to rat chow and tap water. All experiments were previously approved by the institution's Ethics Committee for research on laboratory animals and were performed in accordance with the guidelines for animal care and use set by the National Institutes of Health (USA).
Temperature measurements
Abdominal body temperature was measured in conscious unrestrained rats using data loggers (Subcue data loggers, Calgary, Canada). These were implanted intraperitoneally under ketamine-xylazine (60 mg/kg-7.5 mg/kg) anesthesia and aseptic conditions 1 week prior to the experiment. Animals were treated with oxytetracycline hydrochloride (400 mg/kg i.m.) after surgery. Body temperature was continuously monitored and recorded at 15-min intervals from 2 h before any injection until 6 h after the injection of the pyrogenic stimulus. For the fever index, the abdominal body temperature from baseline (4 measurements preceding any treatment) was determined for each individual animal and the baseline value was subtracted from the individual data points from 2 to 6 h after LPS, SP and CCL3/MIP-1α injection and from 1 to 6 h after IL-1β injection, considering the start time of the febrile response and excluding variations secondary to handling for injection. This approach allows calculation of the area under the curve (AUC) for each individual animal which was used as a fever index expressed in arbitrary units. During the experiment, room temperature was kept at 24°C.
Intracerebral cannula implantation
When necessary, under the same anesthesia described for the implantation of the data loggers, a stainless steel guide cannula (0.8 mm OD, 14 mm in length) was stereotaxically inserted into the right lateral ventricle (Paxinos and Watson, 1998) and fixed to the skull with jeweler's screws embedded in dental acrylic cement. All animals were then promptly treated with oxytetracycline hydrochloride (400 mg/kg) and the experiments were performed 1 week later. After each experiment, the animal was anesthetized as before, and the location of the cannula track was histologically verified. Animals which showed cannula misplacement, blockage upon injection or abnormal weight gain patterns were excluded from the study.
Experimental protocols
A different group of rats was used for each experiment, i.e., each animal was used only once. In a first set of experiments, rats were treated intraperitoneally (i.p.) with either the NK 1 receptor antagonist SR140333B (0.3, 1 or 3 mg/kg dissolved in saline plus Tween 80 1%) or vehicle (2 ml/kg, control), 30 min prior to injection of E. coli LPS (30 μg/kg, i.p.) or sterile saline (2 ml/kg, i.p., control). To confirm the effectiveness of the peripheral treatment, another group of animals was treated with SR140333B (1 mg/kg) and after 30 min, under pentobarbital anesthesia (50 mg/kg, i.p.), they received an injection of Evans Blue dye (50 mg/kg, i.v.) followed by 40 ng of SP (50 μl) or the same volume of saline in the skin. After 15 min, animals were killed, the dorsal skin was immediately excised and the blue-stained area at each injection site was removed for dye extraction (Rattmann et al., 2008) . The plasma leakage was measured as described previously (Brain and Williams, 1985) . In another set of experiments, rats were treated intracerebroventricularly (i.c.v.) with either the NK 1 receptor antagonist SR140333B (0.3, 1 or 3 μg dissolved in 2 μl saline plus Tween 80 0.3%) or vehicle (2 μl, control), 30 min prior to injection of E. coli LPS (30 μg/kg, i.p.) or sterile saline (2 ml/kg, i.p., control).
In the following set of experiments animals were treated with SR140333B (3 μg/ 2 μl, i.c.v.) or the respective vehicle (Tween 80 0.3%) 30 min prior to injection of the angiotensin convertingenzyme inhibitor captopril (5 μg/ 2 μl, i.c.v.) or the same volume of vehicle (sterile saline), followed by the injection of SP (250, 500 or 750 ng, i.c.v) or saline (2 μl) 30 min later. In the final set of experiments, rats were treated with the same dose of SR140333B or the vehicle 30 min before injecting either IL-1β (3.1 ng/ 2 μl, i.c.v.) or CCL3/MIP-1α (500 pg) or sterile saline. Pyrogenic stimuli were always injected between 10:00 and 11:00 h. Doses of each pyrogenic stimulus were based on previous studies and do not represent doses that cause maximal responses (Fraga et al., 2008; Melo Soares et al., 2006; Werner et al., 2006; Zampronio et al., 2000) .
Drugs
The following drugs were employed: LPS from E. coli 0111:B4, substance P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gli-Leu-Met-NH 2 ) and captopril (Sigma Chem Co., St. Louis, U.S.A.), rat IL-1β and rat CCL3/MIP-1α (R&D Systems Inc., Minneapolis, U.S.A.), oxytetracycline hydrochloride (Terramicina ® , Pfizer, São Paulo, Brazil). SR140333B ((S)1-{3-(3,4-dichloro-phenyl)-3-[2(4-phenyl-1-azabicyclo[2.2.2]oct-1-yl]-ethyl]-piperidin-1-yl}-2-(3-isopropoxyphenyl)-ethanone benzenesulfonate) was a kind gift from Sanofi-Aventis, France.
Statistical analysis
The results are presented as the mean ± S.E.M. The statistical significance among the groups was assessed using one-way analysis of variance followed by Bonferroni's post-hoc test. P values lower than 0.05 were considered an indication of significance.
